Repligen Corporation $RGEN Shares Acquired by Aberdeen Group plc

Aberdeen Group plc raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 17.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 54,330 shares of the biotechnology company’s stock after purchasing an additional 8,152 shares during the quarter. Aberdeen Group plc’s holdings in Repligen were worth $7,262,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in RGEN. AQR Capital Management LLC purchased a new stake in shares of Repligen during the first quarter valued at $262,000. Jones Financial Companies Lllp lifted its stake in shares of Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after buying an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock worth $961,000 after buying an additional 80 shares during the period. Finally, AlphaQuest LLC bought a new position in Repligen during the second quarter worth $104,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In related news, Director Karen A. Dawes sold 275 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.20% of the company’s stock.

Repligen Stock Down 1.1%

RGEN stock opened at $135.68 on Friday. The business has a 50-day moving average of $156.81 and a 200-day moving average of $146.10. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The stock has a market capitalization of $7.64 billion, a P/E ratio of 6,787.39, a P/E/G ratio of 2.50 and a beta of 1.13. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $175.77.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of analyst reports. Wall Street Zen raised shares of Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Barclays upped their price target on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Wells Fargo & Company raised their price objective on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Finally, Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $177.92.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.